- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Domp� Launches Phase 2 Study of Intranasal NGF for Cerebral Palsy
The pharmaceutical company is investigating a new treatment approach for spastic cerebral palsy.
Mar. 30, 2026 at 6:09pm
Got story updates? Submit your updates here. ›
Domp�, a pharmaceutical company, has announced the enrollment of the first patient in a Phase 2 clinical trial evaluating an intranasal form of Nerve Growth Factor (NGF) as a potential treatment for spastic cerebral palsy (CP). The study is taking place in San Mateo, California.
Why it matters
Cerebral palsy is a lifelong condition that can significantly impact a person's mobility and quality of life. New treatment approaches, like the intranasal NGF being studied by Domp�, could help improve outcomes for those living with cerebral palsy.
The details
The Phase 2 study will assess the safety, tolerability, and efficacy of the intranasal NGF treatment in individuals with spastic cerebral palsy. Domp� is investigating this novel delivery method to potentially improve the treatment's ability to reach the affected areas of the brain and nervous system.
- The first patient has been enrolled in the Phase 2 study as of March 30, 2026.
The players
Domp�
A pharmaceutical company developing an intranasal form of Nerve Growth Factor (NGF) as a potential treatment for spastic cerebral palsy.
What’s next
The Phase 2 study is expected to continue enrolling patients and evaluating the intranasal NGF treatment over the next 12-18 months.
The takeaway
This new clinical trial represents an important step forward in exploring innovative treatment approaches for individuals living with the challenges of cerebral palsy. If successful, the intranasal NGF therapy could offer a promising new option to help improve mobility and quality of life for those affected by this condition.
